Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication

KF. Pan, L. Zhang, M. Gerhard, JL. Ma, WD. Liu, K. Ulm, JX. Wang, L. Zhang, Y. Zhang, M. Bajbouj, LF. Zhang, M. Li, M. Vieth, RY. Liu, M. Quante, LH. Wang, S. Suchanek, T. Zhou, WX. Guan, R. Schmid, M. Classen, WC. You,

. 2016 ; 65 (1) : 9-18. [pub] 20150518

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020781
E-zdroje Online Plný text

NLK ProQuest Central od 1960-03-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 1960-03-01 do Před 6 měsíci

Odkazy

PubMed 25986943
DOI 10.1136/gutjnl-2015-309197
Knihovny.cz E-zdroje

OBJECTIVE: To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China. DESIGN: A total of 184,786 residents aged 25-54 years were enrolled in this trial and received (13)C-urea breath test. H. pylori positive participants were assigned into two groups, either receiving a 10-day quadruple anti-H. pylori treatment or lookalike placebos together with a single dosage of omeprazole and bismuth. RESULTS: The prevalence of H. pylori in trial participants was 57.6%. A total of 94,101 subjects completed the treatment. The overall H. pylori eradication rate was 72.9% in the active group. Gender, body mass index, history of stomach disease, baseline delta over baseline-value of (13)C-urea breath test, missed medication doses, smoking and drinking were independent predictors of eradication failure. The missed doses and high baseline delta over baseline-value were important contributors in men and women (all Ptrend<0.001). However, a dose-response relationship between failure rate and smoking or drinking index was found in men (all Ptrend<0.001), while high body mass index (Ptrend<0.001) and history of stomach disease were significant predictors in women. The treatment failure rate increased up to 48.8% (OR 2.87, 95% CI 2.24 to 3.68) in men and 39.4% (OR 2.67, 95% CI 1.61 to 4.42) in women with multiple factors combined. CONCLUSIONS: This large community-based intervention trial to eradicate H. pylori is feasible and acceptable. The findings of this trial lead to a distinct evaluation of factors influencing eradication that should be generally considered for future eradication therapies. TRIAL REGISTRATION NUMBER: ChiCTR-TRC-10000979 in accordance with WHO ICTRP requirements.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020781
003      
CZ-PrNML
005      
20191118124529.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/gutjnl-2015-309197 $2 doi
024    7_
$a 10.1136/gutjnl-2015-309197 $2 doi
035    __
$a (PubMed)25986943
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pan, Kai-feng $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
245    12
$a A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication / $c KF. Pan, L. Zhang, M. Gerhard, JL. Ma, WD. Liu, K. Ulm, JX. Wang, L. Zhang, Y. Zhang, M. Bajbouj, LF. Zhang, M. Li, M. Vieth, RY. Liu, M. Quante, LH. Wang, S. Suchanek, T. Zhou, WX. Guan, R. Schmid, M. Classen, WC. You,
520    9_
$a OBJECTIVE: To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China. DESIGN: A total of 184,786 residents aged 25-54 years were enrolled in this trial and received (13)C-urea breath test. H. pylori positive participants were assigned into two groups, either receiving a 10-day quadruple anti-H. pylori treatment or lookalike placebos together with a single dosage of omeprazole and bismuth. RESULTS: The prevalence of H. pylori in trial participants was 57.6%. A total of 94,101 subjects completed the treatment. The overall H. pylori eradication rate was 72.9% in the active group. Gender, body mass index, history of stomach disease, baseline delta over baseline-value of (13)C-urea breath test, missed medication doses, smoking and drinking were independent predictors of eradication failure. The missed doses and high baseline delta over baseline-value were important contributors in men and women (all Ptrend<0.001). However, a dose-response relationship between failure rate and smoking or drinking index was found in men (all Ptrend<0.001), while high body mass index (Ptrend<0.001) and history of stomach disease were significant predictors in women. The treatment failure rate increased up to 48.8% (OR 2.87, 95% CI 2.24 to 3.68) in men and 39.4% (OR 2.67, 95% CI 1.61 to 4.42) in women with multiple factors combined. CONCLUSIONS: This large community-based intervention trial to eradicate H. pylori is feasible and acceptable. The findings of this trial lead to a distinct evaluation of factors influencing eradication that should be generally considered for future eradication therapies. TRIAL REGISTRATION NUMBER: ChiCTR-TRC-10000979 in accordance with WHO ICTRP requirements.
650    _2
$a dospělí $7 D000328
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a protivředové látky $x terapeutické užití $7 D000897
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a infekce vyvolané Helicobacter pylori $x komplikace $x diagnóza $x farmakoterapie $7 D016481
650    12
$a Helicobacter pylori $7 D016480
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metronidazol $x terapeutické užití $7 D008795
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a nádory žaludku $x mikrobiologie $x prevence a kontrola $7 D013274
650    _2
$a tetracyklin $x terapeutické užití $7 D013752
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Čína $7 D002681
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zhang, Lian $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Gerhard, Markus $u Technische Universität München, Munich, Germany.
700    1_
$a Ma, Jun-ling $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Liu, Wei-dong $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Ulm, Kurt $u Technische Universität München, Munich, Germany.
700    1_
$a Wang, Jian-xi $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Zhang, Lei $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Zhang, Yang $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Bajbouj, Monther $u Technische Universität München, Munich, Germany.
700    1_
$a Zhang, Lan-fu $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Li, Ming $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Vieth, Michael $u Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany.
700    1_
$a Liu, Rui-yong $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Quante, Michael $u Technische Universität München, Munich, Germany.
700    1_
$a Wang, Le-hua $u Healthy Bureau of Linqu County, Weifang, China.
700    1_
$a Suchánek, Štěpán $u Department of Medicine, 1st Faculty of Medicine, Military University Hospital, Charles University, Prague, Czech Republic. $7 xx0105313
700    1_
$a Zhou, Tong $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Guan, Wei-xiang $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
700    1_
$a Schmid, Roland $u Technische Universität München, Munich, Germany.
700    1_
$a Classen, Meinhard, $d 1936-2019 $7 nlk20030128123 $u Technische Universität München, Munich, Germany International Digestive Cancer Alliance, Germany.
700    1_
$a You, Wei-cheng $u Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
773    0_
$w MED00009778 $t Gut $x 1468-3288 $g Roč. 65, č. 1 (2016), s. 9-18
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25986943 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20191118124809 $b ABA008
999    __
$a ok $b bmc $g 1155451 $s 945309
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c 1 $d 9-18 $e 20150518 $i 1468-3288 $m Gut $n Gut $x MED00009778
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace